Over the past 30 years, with the gradual deepening of scientists’ understanding of the mechanism of IL17 family, the efficacy of targeted IL17 family drugs in autoimmune diseases, including psoriasis and ankylosing spondylitis, has been confirmed by more and more studies [50,60]. The gene discussed is IL17A; the disease is ankylosing spondylitis.